Inhibitors
Cat.No. | Name | Information |
---|---|---|
M10818 | FT827 | FT827 is a selective covalent inhibitor of ubiquitin-specific protease 7 (USP7) (Ki=4.2 µM)。 FT827 with USP7 Catalytic Domain (USP7CDresidues 208-560) combined, apparent Kd The value is 7.8 μM. |
M10817 | FT671 | FT671 is a potent, non-covalent, selective USP7 inhibitor,IC50 The value is 52 nM, bound to the USP7 catalytic domain Kd The value is 65 nM. |
M10753 | VLX1570 | VLX1570 is a competitive inhibitor of proteasome deuteronase (DUBs),IC50 约10 μM。 |
M10752 | GNE-6776 | GNE-6776 is a potent, selective USP7 inhibitor with oral activity. |
M10504 | IU1-47 | IU1-47 is a potent and specific USP14 inhibitor with an IC50 of 0.6 μM. |
M9871 | GSK2643943A | GSK2643943A is a deubiquitylating enzyme (DUB) inhibitor targeting USP20/Ub-Rho with an IC50 of 160 nM. |
M9785 | ML364 | ML364 is a small molecule inhibitor of the deubiquitinase USP2 (IC50=1.1 μM) with potential anticancer activity. |
M9654 | GRL0617 | GRL0617 is a potent, selective and competitive noncovalent inhibitor of SARS PLPro, with IC50 of 0.6 μM and Ki of 0.49 μM. |
M9639 | SJB2-043 | SJB2-043 is an inhibitor of USP1 which targets ID1 degradation in leukemic cells. |
M2807 | LDN-57444 | LDN-57444 is a reversible, competitive proteasome inhibitor for Uch-L1 with IC50 of 0.88 μM, 28-fold selectivity over isoform Uch-L3. |
M2565 | PR-619 | PR-619 is a non-selective, reversible inhibitor of the deubiquitinylating enzymes (DUBs) with EC50 of 1-20 μM. |
M2431 | b-AP15 | b-AP15 is a deubiquitinases inhibitor for 19S proteasomes activity of Ub-AMC cleavage with IC50 of 2.1 μM. *The compound is unstable in solutions, freshly prepared is recommended |
M2196 | P22077 | P22077 is a selective inhibitor of ubiquitin-specific protease (USP) 7 with EC50 of 8.6 μM. |
M2195 | P5091 | P5091 is a potent and selective inhibitor of ubiquitin-specific protease (USP) 7 with IC50 of 4.2 μM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.